Perspective for safer alternatives. COX-2-selective NSAID's;COX-2-selective NSAID's: Opties voor veiliger alternatieven

Pharmaceutisch Weekblad

Volumn 135, Issue 5, 2000, Pages 162-167

  Van Roon, E N ^a   Brouwers, J R B J ^b   Posthuma, R M ^a  

^a Tjongerschans te Heerenveen ^*

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Anti inflammatory agents, non steroidal; Pain; Prostaglandin endoperoxide synthetase; Rheumatic diseases

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; MELOXICAM; MESSENGER RNA; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; HUMAN; INFLAMMATION; PAIN; RHEUMATIC DISEASE; STRUCTURE ACTIVITY RELATION;

EID: 0034602952     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Steen KSS, Lenis WF, Dijkmans BAC. Effectiviteit, veiligheid en kosten van strategieën ter preventie van gastropathie door gebruik van niet-steroïde anti-inflammatoire geneesmiddelen. Ned Tijdschr Geneeskd 1999;143:1649-52.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-5.
3. Campbell WB. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Gilman AG, Rall TW, Nies AS, Taylor P, red. Goodman and Gilman's the pharmacological basis of therapeutics. 8e ed. Elmsford: Pergamon Press, 1990:600-17.
4. Seibert K, Masferrer JL, Fu JY, et al. The biochemical and pharmacologic manipulation of cellular cyclooxygenase (COX) activity. Adv Prostaglandin Thromboxane Leukot Res 1991;21:45-51.
5. Crofford L COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997;24:S15-9.
6. Jouzeau J-Y, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-82.
7. Lipsky PE, Abramson SB, Crofford L, et al. The classification of cyclooxygenase inhibitors J Rheumatol 1998;25:2298-303.
8. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999;38:779-88.
9. Kurumbail RG, Stevens AM, Gierske JK, et al. Structural basis for selective inhibition of cyxlo-oxygenase 2 by anti-inflammatory agents. Nature 1996;384:644-8.
10. Simmons DL, Botting RM, Robertson PM, et al. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugs. Proc Natl Acad Sci USA 1999;96:3275-80.
11. Simon LS. Nonsteroidal antiinflammatory drugs and their effects. The importance of COX selectivity. J Clin Rheumatol 1996;2:135-40.
12. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
13. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclo-oxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
14. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999;19:1269-78.
15. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 1999;282:1921-8.
16. Product Information. Vioxx (rofecoxib tablets and oral suspension). West Point: Merck & Co., Inc., 1999.
17. Morrison BW, Christensen S, Yuan W, et al. Analgesic efficacy of the cyclooxynase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trail. Clin Ther 1999;21-943-53.
18. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;3:336-47.
19. Product Information. Celebrex (celecoxib capsules). New York: GD Searle & Co., 1998.
20. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAID's. JAMA 1999;282:1929-33.
21. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
22. Garcia Rodriguez LA Non-steroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997;26:16-20.
23. Wolfe MM. Future trends in the development of safer nonsteroidal antiinflammatory drugs. Am J Med 1998;105 suppl 5A:44S-52S.
24. Kaplan-Machlis B, Storyk Klostermeyer B. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-88.
25. Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 1997;24:9-14.
26. Ehrich EW. Early clinical experience with MK-966, a highly specific inhibitor of COX-2. The XIX ILAR Congress of Rheumatology; 1999 Jun 9; Singapore.
27. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
28. Mohammed S, Croom DW II. Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor [brief]. N Engl J Med 1999;340:2005-6.
29. Thun MJ, Namboodiri MM, Heath CJW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1734-7.
30. Giovanucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
31. Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians Health Study. Ann Intern Med 1998;128:713-20.
32. Gupta RA, Dubois RN Aspirin, NSAID's, and colon cancer prevention: mechanisms? [Editorial]. Gastroenterology 1998;114:1095-100.
33. Wunsch H. COX provides missing link in mechanism of aspirin in colon cancer. Lancet 1998;351:1864.
34. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-32.
35. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
36. In 't Veld BA. Launer LJ, Hoes AW, et al. NSAID's and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998;19:607-11.
37. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology 1995;45.51-55.
38. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
39. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201